Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

Lyon-II, 3000 - Ticlopidine vs placebo

Gardecki, 3000 - Ticlopidine vs placebo

ADVANCE 2, 2010 - apixaban vs enoxaparin (europe regimen)

ADVANCE 3, 2010 - apixaban vs enoxaparin

RECORD 4, 2009 - rivaroxaban vs enoxaparin (US regimen)

WATCH (warfarin vs aspirin), 2009 - warfarin vs aspirin

RECORD 2, 2008 - rivaroxaban (long duration) vs enoxaparin (short duration)

RE-MOBILIZE (220mg), 2008 - dabigatran 220mg vs enoxaparin (US regimen)

ADVANCE-1, 2008 - apixaban vs enoxaparin (US regimen)

RECORD 1, 2008 - rivaroxaban vs enoxaparin

DRIVE, 2008 - SR123781A vs enoxaparin

RECORD 3, 2008 - rivaroxaban vs enoxaparin (europe regimen)

RE-MOBILIZE (150mg), 2008 - dabigatran 150mg vs enoxaparin (US regimen)

RE-MODEL (220mg), 2007 - dabigatran 220mg vs enoxaparin (europe regimen)

RE-NOVATE (150mg), 2007 - dabigatran 150mg vs enoxaparin

APROPOS 2.5mg, 2007 - apixaban vs enoxaparin (US regimen)

RE-MODEL (150mg), 2007 - dabigatran 150mg vs enoxaparin (europe regimen)

RE-NOVATE (220mg), 2007 - dabigatran 220mg vs enoxaparin

Cohen (L8405), 2007 - compression stocking group vs control (on top fondaparinux)

HELAS (warfarin vs aspirin), 2006 - warfarin vs aspirin

ODIXa-HIP 10mg, 2006 - rivaroxaban vs enoxaparin (short duration)

ODIXa-KNEE, 2005 - rivaroxaban vs enoxaparin (US regimen)

WASH (warfarin), 2004 - warfarin vs no treatment

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004 - triflusal+coumadin medium dose vs triflusal

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004 - triflusal+coumadin medium dose vs coumadin standard dose



See also:

  • All DVT prophylaxis clinical trials
  • All clinical trials of new anticoagulants
  • All clinical trials of dabigatran 150mg
  •  

    RE-MOBILIZE (150mg) study, 2008

    Facebook    pdf : dabigatran 150mg - antithrombotics for DVT prophylaxis

    Treatments

    Studied treatment dabigatran etexilate 150 mg q.d. for 12-15 days
    started 6 to 12 hours after completion of surgery
    Control treatment enoxaparin 30 mg SC BID after surgery for 12-15 days
    started 12 to 24 hours after surgery, usually on the morning after the day of surgery
    Concomittant treatment
    Remarks
    Treatments description
    enoxaprin regimen started after surgery 
    treatment duration 12-15 days 

    Patients

    Patients Total knee replacement
    Inclusion criteria Patients 18 years or older and weighing more than 40 kg who had undergone primary elective unilateral total knee arthroplasty
    Exclusion criteria known inherited or acquired clinically significant bleeding disorder; major surgery, trauma, uncontrolled hypertension, or myocardial infarction within the last 3 months; history of acute intracranial disease or hemorrhagic stroke; gastrointestinal or urogenital bleeding or ulcer disease within the last 6 months; severe liver disease; aspartate or alanine aminotransferase (AST, ALT) levels higher than 2x the upper limit of the normal range (ULN) within the last month; severe renal insufficiency (creatinine clearance <30 mL/min); need for concomitant longacting nonsteroidal anti-inflammatory drug therapy or treatment with an anticoagulant during study drug treatment; active malignant disease; platelet count less than 100 × 10^9/L,
    Remarks
    Baseline characteristics
    Age (mean), years 66y 
    Total hip replacement 0% 
    Total knee replacement 100% 
    Weight, kg, 88kg 
    Female 57% 
    general anesthesia 53% 
    BMI (kg/m²) NA 
    History of venous thromboembolism (%) NA 
    Use of cement NA 
    Estimated creatinine clearance >60 ml/min NA (mean clearance 82.9 ml/min) 
    Previous orthopedic surgery (%) NA 
    Duration of surgery (min) 91 min 

    Method and design

    Randomized effectives 877 / 876 (studied vs. control)
    Blinding double blind
    Follow-up duration 12-15 days, median 14d
    Number of centre 97
    Geographic area US, Canada, Mexico, UK
    Hypothesis Non inferiority
    Primary endpoint total VTE and all-cause mortality
    Remarks

    Remarks / Comments



    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    All cause death

    1 / 877
    0 / 876
    classic 4,99 [0,07;365,56]

    major or clinically relevant non-major bleeding

    27 / 871
    33 / 868
    0,82 [0,49;1,34]

    non-fatal pulmonary embolism

    0 / 649
    5 / 643
    classic 0,05 [0,00;2,60]

    major VTE (fatal and non fatal DVT,PE)

    20 / 656
    15 / 668
    classic 1,36 [0,70;2,63]

    total VTE and all-cause mortality

    219 / 649
    163 / 643
    1,33 [1,12;1,58]

    distal DVT

    198 / 649
    148 / 643
    1,33 [1,10;1,59]

    Major bleeding

    5 / 871
    12 / 868
    0,42 [0,15;1,17]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    major or clinically relevant non-major bleeding 27 / 871 (3,1%) 33 / 868 (3,8%) 0,82 [0,49;1,34]   12103 
    All cause death 1 / 877 (0,1%) 0 / 876 (0,1%) 2,00 [0,07;59,47]   12103 
    non-fatal pulmonary embolism 0 / 649 (0,1%) 5 / 643 (0,8%) 0,10 [0,01;1,81]   12103 
    Major bleeding 5 / 871 (0,6%) 12 / 868 (1,4%) 0,42 [0,15;1,17]   12103 
    total VTE and all-cause mortality 219 / 649 (33,7%) 163 / 643 (25,3%) 1,33 [1,12;1,58]   12103 
    distal DVT 198 / 649 (30,5%) 148 / 643 (23,0%) 1,33 [1,10;1,59]   12103 
    major VTE (fatal and non fatal DVT,PE) 20 / 656 (3,0%) 15 / 668 (2,2%) 1,36 [0,70;2,63]   12103 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 12103: Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JAOral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.J Arthroplasty 2009;24:1-9

  • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    major or clinically relevant non-major bleeding 3,10% 3,80% -7,0‰
    Major bleeding 5,74‰ 1,38% -8,1‰
    total VTE and all-cause mortality 33,74% 25,35% 8,4%
    distal DVT 30,51% 23,02% 7,5%
    major VTE (fatal and non fatal DVT,PE) 3,05% 2,25% 8,0‰

    Meta-analysis of all similar trials:

    anticoagulant in DVT prophylaxis for orthopedic surgery

    antithrombotics in DVT prophylaxis for elective major knee surgery

    antithrombotics in DVT prophylaxis for orthopedic surgery

    direct antithrombins in DVT prophylaxis for all type of patients

    new anticoagulants in DVT prophylaxis for elective major knee surgery

    new anticoagulants in DVT prophylaxis for orthopaedic surgery

    new anticoagulants in DVT prophylaxis for all type of patients



    Reference(s)

    Trials register # NA
    • Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.. J Arthroplasty 2009;24:1-9 - 10.1016/j.arth.2008.01.132
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend